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Letters to the EditorPatients in our study with heterotaxy
and congenital heart disease (CHD)
showed high postoperative morbidity/
mortality, with some having respiratory
complications.2 Although this respira-
tory phenotype is often attributed to
the CHD, airway mucus clearance and
left-right patterning, abnormal in heter-
otaxy syndrome, both require motile
ciliary function. Thus airway ciliary
dysfunction (CD) similar to that of pri-
mary ciliary dyskinesia (PCD) may
have relevance for increased respiratory
complications seen in patientswith het-
erotaxy. To better characterize the phe-
notype of a broad spectrum of patients
with heterotaxy, 43 patients with CHD
were assessed for airway CD. We
used videomicroscopy to look for ab-
normal ciliary motion in nasal tissue
and nasal nitric oxide noninvasive test-
ing (typically low with PCD) to assess
for CD. A remarkable 42% (18/43) of
patients exhibited CD, with one third
in the severe PCD range. Patients
greater than 6 years old with CD
showed increased respiratory disease
similar to that seen in PCD.3 Our stud-
ies suggest patients with CHD who
have heterotaxy have substantial risk
of CD and respiratory disease that
complicates their prognosis.
The phenotype–genotype–progno-
sis correlation is also important in
that further research may allow future
patients and families to correlate gene
mutations with phenotype and progno-
sis. Now families face the very high re-
currence risk ratio of 79.1 for
heterotaxia (95% confidence interval,
32.9-190).4 Further study of our pa-
tients with heterotaxy who have CD
through next-generation sequencing
of all 14 known PCD genes in 13 heter-
otaxy patients with CD identified 10
novel coding variants in 6 PCD genes.
Recently, some CD gene mutations
have become commercially available.
The paradigm of phenotype–geno-
type–prognosis is beneficial to pro-
mote translational research to the
patient, family, and medical care
team. Our research suggests that pa-
tients with CHD and heterotaxy will760 The Journal of Thoracic and Cbe at higher perioperative risk if they
have CD.3 These findings indicate
that patients with CHD and heterotaxy
may benefit from preoperative screen-
ing for CD. Recognition of specific
surgical risks factors in genetic syn-
dromes is leading to specific diagnostic
protocols that improve phenotyping or
predictive genotyping.1 To add ‘‘ther-
apy’’ to the paradigm, further studies
are needed to evaluate whether perio-
perative protocols improving airway
ciliary motility and enhancing mucus
clearancemay reduce respiratory com-
plications and improve postoperative
outcome for patients with CHD who
have heterotaxy and CD.
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AMPLATZER SEPTAL
OCCLUDER DEVICE
To the Editor:
We read with interest the article
‘‘Late erosion of an Amplatzer septalardiovascular Surgery c March 2012occluder device 6 years after place-
ment’’ by Taggart, Dearani, and
Hagler1 in the Journal of Thoracic
and Cardiovascular Surgery.
It is assumed that cardiac perfora-
tion is a rare complication following
transcatheter device closure of an atrial
septal defect (ASD) or patent foramen
ovale (PFO). We, too, had a patient
who had similar complications of per-
foration 9 months after closure of an
ASD with a BioSTAR septal occluder
(NMT Medical, Boston, Mass).2 An-
other patient came to us 3 years after
ASD closure with a Solysafe device
(Swissimplant AG, Solothurn, Swit-
zerland) with complications of device
fracture and embolization into the pul-
monary artery. Our patients warranted
emergency surgical exploration for de-
vice explantation, repair of the erosion,
along with pericardial patch closure of
the residual septal defect. Although in-
novative absorbable closure devices
that gradually biodegrade after implan-
tation have theoretically decreased the
long-term complications, it must be
borne in mind that these devices are
not totally bioabsorbed. The nonab-
sorbable components, such as the
metal struts, may create long-term
complications by eroding into the adja-
cent tissues.
This case clearly illustrates that in-
asmuch as tissue erosion, and other
complications such as strut fracture,
may occur at any time starting from
72 hours to 6 years after implantation,
echocardiographic follow-up is
needed, not just in the early stages,
but also in the long-term. We also be-
lieve that clearer guidelines and rec-
ommendations may help prevent the
complications associated with septal
occluder devices.
Although cardiac perforation may
be ‘‘rare,’’ it is a potentially ‘‘seri-
ous’’ complication after transcatheter
device closure procedures. These pa-
tients arrived at the hospital in time
to benefit from immediate diagnosis
and emergency surgical treatment of
their complications. The question
we need to ask ourselves and also
Letters to the Editorfor our patients is whether the main
‘‘advantage’’ of transcatheter device
closure, namely, its minimally inva-
sive nature, is really worth taking
the risk of having a life-threatening
complication at a later date, requiring
emergency surgery with eventual sur-
gical closure of the septal defect. In
contrast, primary surgical closure of
an ASD/PFO through a minithoracot-
omy/ministernotomy is a safe and ef-
fective minimally invasive procedure,
without the risk of erosion.
It is possible that some patients may
have had only minor complications af-
ter transcatheter device closure, with-
out the severe clinical complications
presented in our case reports. Further-
more, how many centers are really
reporting all the postimplantation
complications? How many patients
are being followed up to assess long-
term complications?
The other question we should ask
ourselves is, ‘‘Are we really only see-
ing the tip of the iceberg?’’ Moreover,
is even the tip of the iceberg really
much bigger than what is being
presented?
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doi:10.1016/j.jtcvs.2011.10.087Reply to the Editor:
We appreciate the conscientious
input by Cherian, Kalangos, andThe JournalCikirikcioglu regarding the risk of
erosion associated with Amplatzer
septal occluder devices (AGA Medi-
cal Corporation, Golden Valley,
Minn). We likewise acknowledge
that we do not know the true timeline
of device erosions. This uncertainty
may create some unease among cardi-
ologists and surgeons, but it should
not necessarily dissuade us from
catheter-based treatment of atrial sep-
tal defects (ASDs). Certainly, one may
speculate about icebergs, but there is
little evidence of those here. The fact
remains that device erosion is rare;
current postmarket study of the Am-
platzer septal occluder device place-
ment may provide some insight into
the true incidence of erosions.
Although the letter raises important
questions to consider before selecting
a transcatheter or surgical approach to
treatment of ASDs, we disagree with
the implication that erosion is an inher-
ent risk of transcatheter ASD closure.
The 2 devices mentioned in the letter
(BioSTARandSolysafe) both have stiff
arms, which may perforate and have
been removed from the US market. In
addition, the Gore Helex device (W.
L. Gore & Associates, Inc, Flagstaff,
Ariz) has not been associated with any
erosions and may represent a safe
alternative to surgical intervention.
What we can all agree on is that
discussions such as this one are vital
to developing safer, less invasive treat-
ment strategies for patients with con-
genital heart disease.
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BRAIN AND SPINAL CORD FOR
PERFUSION STUDIES
To the Editor:
We were a little puzzled during our
reading of Al-Ali and colleagues’of Thoracic and Cardiovascular Surgerecent article.1 They mentioned that
the brain and spinal cord were photo-
graphed and then carefully removed
en bloc. Because the epidural space
between spinal cord and vertebrae is
small, spinal cord removed en bloc
was not easy even if the spinal cords
were fixed. Which methods and
equipment were applied by Al-Ali
and colleagues? In our experience,
the vertebral column and cranium
was decalcified first. Then craniot-
omy and laminectomy were easily
performed to expose the brain and
spinal cord in situ. The brain and spi-
nal cord could then be removed en
bloc.
In the study of Al-Ali and col-
leagues,1 the length of filling in the an-
terior and posterior spinal arteries was
also measured and then converted into
a percentage of the total length of the
cord. Sometimes, however, spinal ar-
teries, especially the posterior spinal
artery, are absent or partially absent
(Figure 1). What did they do in such
cases?
Al-Ali and colleagues reported
measuring the length of the spinal
cord from the brainstem to the conus
medullaris.1 In our experience, ac-
curately identifying the initial point
of the cauda equina is very hard
without incision of the dura mater.
How did Al-Ali and colleagues ac-
curately distinguish between the
conus medullaris and the cauda
equina?
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